<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BE22AA55-DA2E-4D89-AEF7-56C1607432A1"><gtr:id>BE22AA55-DA2E-4D89-AEF7-56C1607432A1</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Forbes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D029004-264F-482F-9306-9CD1E6B8AC1B"><gtr:id>6D029004-264F-482F-9306-9CD1E6B8AC1B</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Iredale</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0600033"><gtr:id>3B76017F-37B7-4CE5-AC9D-FA9F60BEFB89</gtr:id><gtr:title>The role of elastin degradation in the pathogenesis of liver fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600033</gtr:grantReference><gtr:abstractText>Long term or chronic liver disease, regardless of cause, results in scarring of the liver (termed fibrosis and cirrhosis). This scarring causes the liver to fail and is associated with significant illness and death. In the UK, the burden of cirrhosis has been identified by the Chief Medical Officer as a major challenge of the next decade. Currently there are no effective treatments for liver scarring. We have a programme of research investigating the factors which regulate recovery from scarring to inform and develop anti-scarring (so called anti-fibrotic) therapies.

We have recently demonstrated that if it is allowed to, the liver has a significant ability to break the scar tissue with a return towards more normal structure and function. In advanced liver disease though, the scar tissue persists and appears to be resistant to break-down. The presence of a protein called elastin seems to be critical to preventing effective breakdown of the scar tissue. In addition, we have preliminary evidence to suggest that a specialised form of inflammatory cell, the macrophage, produces a specific protein (enzyme) which breaks down elastin. Taken together these results suggest that elastin characterises irreversible scarring (cirrhosis) and that it accumulates as a result of a failure of the normal processes of breakdown.

Work we are undertaking will determine the cell source of elastin and the elastin degrading proteins and their relative levels at different stages of liver scarring (reversible and irreversible).
In addition, we will use experimental models to determine the mechanisms that make scarring resistant to breakdown and use infusions of purified inflammatory cells and specific population of stem cells to enhance scar breakdown.

Ultimately, by understanding the mechanisms regulating the turnover of elastin in liver scarring we will be better able to design effective anti-scarring therapies applicable in the clinic.</gtr:abstractText><gtr:technicalSummary>Currently there are no effective treatments for liver fibrosis and cirrhosis which represent major health challenges worldwide. Therefore, there is a pressing need to develop antifibrotic therapies. We have recently demonstrated that experimental liver fibrosis is reversible and that reversal is characterised by matrix degradation and apoptosis of activated (myofibroblast-like) hepatic stellate cells (the major cell mediator of fibrosis). However, following prolonged experimental injury, fibrosis develops which is not degraded even after one year of recovery. Characterisation of the septa which fail to undergo degradation indicates that they contain elastin, in contrast to those which rapidly become remodelled, which do not. These septa are also crosslinked by tissue transglutaminase (tTG), for which elastin is a substrate.
 In pilot studies, we have shown elastase (MMP-12) is expressed in the liver by tissue macrophages and after conditional depletion of macrophages, hepatic elastin degradation is impaired; indicating that the macrophages are critical to spontaneous recovery from fibrosis and are an important source of MMP-12. 
 We propose to investigate the hypotheses that: A failure of elastin degradation characterises mature liver fibrosis. The presence of elastin facilitates matrix cross-linking which becomes resistant to MMP mediated degradation and persists even during spontaneous resolution. Initially, we propose to quantitate the relative expression, distribution and cellular source of elastin and MMP-12 in rodent models of reversible and irreversible fibrosis. These will be completed by studies of cirrhotic human liver tissue. MMP-12 knockout mice and wild type mice will be examined after induction of liver fibrosis by CCl4 injection and during spontaneous recovery to examine whether elastin persistence results from a failure of elastin degradation. We will go on to ?rescue? the phenotype of MMP-12 knockout mice by restoring a wild type macrophage genotype via either haemopoetic stem cell infusion or direct macrophage injection from wild type animals. We will use DTR mice to examine in detail the effect of selective macrophage depletion on the degradation of elastin and fibrotic tissue in livers undergoing spontaneous recovery from experimentally induced liver fibrosis. Finally we will use a novel model to determine the relative role of stellate cell/myofibroblast derived MMP-12 vs macrophage derived MMP-12 in matrix turnover by seeding the hepatic scar with MMP-12 knockout stem cell derived stellate cells or macrophages. By completion of these studies we will have defined the role of elastin and regulation of its degradation by MMP-12 in the spontaneous resolution of liver fibrosis.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1092223</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Reproductive Health</gtr:department><gtr:description>polymers for growing cells</gtr:description><gtr:id>76974A74-C7CF-4727-B502-759A3818F0E3</gtr:id><gtr:impact>Patent : (WO/2010/106345) POLYMERS FOR GROWING CELLS</gtr:impact><gtr:partnerContribution>Added a multidisciplinary component to the MRC CIRAs before</gtr:partnerContribution><gtr:piContribution>Providing liver biology expertise for extended culture of functional human hepatocyte like cells</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Imaging Liver Fibrosis</gtr:description><gtr:id>C896D68A-016A-48FA-8DCF-C57FF06CAB00</gtr:id><gtr:impact>None at present</gtr:impact><gtr:piContribution>I have acted a s a consultant to the above facilitating the development of the above programme.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Edinburgh</gtr:department><gtr:description>polymers for growing cells</gtr:description><gtr:id>EF5396C0-E4C9-483D-AD2B-A9B8C626A228</gtr:id><gtr:impact>Patent : (WO/2010/106345) POLYMERS FOR GROWING CELLS</gtr:impact><gtr:partnerContribution>Added a multidisciplinary component to the MRC CIRAs before</gtr:partnerContribution><gtr:piContribution>Providing liver biology expertise for extended culture of functional human hepatocyte like cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Identifying Antifibrotic Targets</gtr:description><gtr:id>9A70ED9F-A941-44D9-BB5B-5C2A2B0531E2</gtr:id><gtr:impact>Currently discusing clinical application of relaxin as antifibrotic and portal hypotensive agent</gtr:impact><gtr:partnerContribution>Novartis and their predecessor Corthera have supplied recombinant relaxin and worked with us on the deployment of relaxin as an antifibrotic and portal hypotensive agent. We are currently in discussions over the feasibility of an experimental medicine study in human subjects</gtr:partnerContribution><gtr:piContribution>I have acted as a consultant to the above facilitating the development of the above programme.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Inaugural Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A09D1321-F75E-42AA-B935-CFB77DD411E9</gtr:id><gtr:impact>1 hour public lecture with reception afterwards.

Wide ranging audience from high school students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary Futures: Who's in Health? campaign launch</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7ECBC604-5989-4581-938B-2599773230ED</gtr:id><gtr:impact>Iredale launched &amp;quot;Who's in Health&amp;quot; in Scotland with the Chief Medical Officer for Scotland, Dr Catherine Calderwood at Sciennes Primary School in Edinburgh on the 1st of December. This event launched the Primary Futures Campaign to help young children understand how people in the health sector use literacy, maths and science in their jobs.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://news.scotland.gov.uk/News/Primary-Futures-Who-s-In-Health-1fd9.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BASL and AASLD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>697A04D9-EA64-4297-97E0-92941649A912</gtr:id><gtr:impact>Presentations have been made by our group at the major UK and North American liver disease meetings: BASL and AASLD.

Presentations at the AASLD have recieved the President's commendation (top 10% of scientific presentations)</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7BC8670B-794B-4D4E-9DBB-60C1AD0F9961</gtr:id><gtr:impact>A public presentation with colleagues from Oxford and KCL exploring the potential of regenerative medicine. This was followed by an informal public breakout session. The presentation comprised MRC's contribution to the Times Cheltenham Science Festival June 2012.

Wide ranging audience comprising members of the public, patients and other interested parties. Uniformly positive feedback received.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Detectives Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31318F94-478A-4C3E-A446-E74F689A4230</gtr:id><gtr:impact>a public lecture as part of a series celebrating Conan Doyle's medical studentship in Edinburgh 45 mins with discusion, wide ranging audience from high school students to pensioners

it was posted on youtube and I have received feedback from around the world</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>236467</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship (Dr A Robson)</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>052CA074-21B2-463D-B587-73AC24E7C0BA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244706</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust STMTI Fellowship (V Snowdon)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>096528</gtr:fundingRef><gtr:id>12039779-B06A-4988-A4D0-28AE5B6C4B74</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust PhD Portfolio for Clinicians (ECAT)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>1C3CD3BF-9DE7-4485-8BF6-B98E42CF69B5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant (with S Forbes)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>88D9F5BE-E672-42BE-8546-077E5169FD9F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>241552</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant (Mole)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>3C3115D7-4202-45B0-A843-C1E74A0517E0</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1480000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CIR Centre Core Support Grant - Renewal</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FFB1E392-1D68-4642-8F17-B04E70B53F47</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKSCF/UK Stem Cell Foundation</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>UK Stem Cell Foundation</gtr:fundingOrg><gtr:id>C0732F80-4A50-4EFE-AC87-304402886E8E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>668183</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Equipment Grant (Mullins)</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>394C5A56-DBD6-4663-8ABE-9D3C397A37A9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1350</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal College of Surgeons Vacation Bursary (Ms Aysha Ali)</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Royal College of Surgeons of England</gtr:fundingOrg><gtr:id>DB616D3F-F7B4-4437-883C-C00E6E523A58</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>867024</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Intermediate Fellowship (T Kendall)</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>095898</gtr:fundingRef><gtr:id>C19DFBE8-45A4-4B3F-B6B7-DF66A59992DD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Collaborative Pogramme Grant (Prof CP Day)</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>54A693E5-688B-421F-8AEF-4F99EEC320EA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem Cells for Safer Medicine (Hay &amp;amp; Brickman)</gtr:description><gtr:fundingOrg>Stem Cells for Safer Medicines (SC4SM)</gtr:fundingOrg><gtr:id>93769EBB-FA51-4DCA-B948-3B25C3DB2A3F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fellowship (Fallowfield)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>AB7C0CC6-AECF-4CE7-B6C6-042EE6D87358</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>743397</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academy of Medical Sciences Intermediate Fellowship (Dr J Fallowfield)</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>AD5D598D-F80D-4FA4-AB63-D0EBBC1B4F1F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Vacation Scholarship (Pei Pei Lee)</gtr:description><gtr:end>2009-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>7E69C343-C29A-496C-B1E4-44B7541419C3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140937</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Technology Strategy Board Grant Roslin Cellab</gtr:description><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>69588CFC-E71C-4A30-BC7F-66D078A07A7C</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>239000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship (Dr M Gibbons)</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A9909CE5-E76D-449B-B7C4-A940AFE0EA1D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council Programme Renewal</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>01B1A176-20F6-4F3E-951F-4CF25EABEEAB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>538239</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academy of Medical Sciences Intermediate Fellowship (Dr D Mole)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>33D258E3-16DE-47D8-8F70-FD28928384B9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>242492</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Research Training Fellowship (Dr P Ramachandran)</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>E0FA861C-3683-42FC-A320-F20D850D0889</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>268000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Strategic Grant (Forbes/Knight)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2EA16257-8D70-4282-8516-37C35B290656</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Vacation Scholarship (M Rygier)</gtr:description><gtr:end>2009-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>1BEA3C9A-8976-4C5B-B2B6-1B68E8E5464C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>877220</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Intermediate Fellowship (Dr N Henderson)</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>38E8F270-86F1-403F-9C15-9CD0F6B74F20</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>223799</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship (Dr T Gordon-Walker)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DAE4022E-94C4-4474-92A0-0A52EEAB7793</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Research Training Fellowship (Dr T Bird)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>AAF14EA3-BBFE-42BB-A008-43FAD349D9A5</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>135404</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Research Training Fellowship (Dr D McFarlane)</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>EECE1D3B-A980-4A54-872C-69357DA54B60</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention provides a polymer substrate for use in the attachment and functioning of hepatocyte and hepatocyte like cells. In particular, the polymer substrate is a polyurethane polymer.</gtr:description><gtr:id>537E5A6C-58DC-45C9-8C93-4D5C0A19698C</gtr:id><gtr:impact>The ability to culture functional human heptocyte like cells over long periods of time in vitro</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2010106345</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Polymers for growing cells</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The present invention provides a polymer substrate for use in the attachment and functioning of hepatocyte and hepatocyte like cells. In particular, the polymer substrate is a polyurethane polymer.</gtr:description><gtr:id>AD9F2048-EB0A-4507-B103-322D1ECEBAE1</gtr:id><gtr:impact>Ability to maintain functional human hepatocyte like cells for extended periods of culture in vitro</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Polymers for growing cells</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have employed ActivinA and Wnt3a signalling to produce efficient levels of hepatocyte like cells (approximately 90%) which display hepatic function, including: ureagenesis, gluconeogenesis, albumin secretion and CYP1A2 activity from hESCs and iPSCs (Hay etal.,2008 ; Sullivan etal.,2010). Although hepatic endoderm (HE) generated from hESCs and iPSCs is a genotypically diverse, cheap and stable source of &amp;quot;hepatocytes&amp;quot;, HE routine application is limited due to phenotypic instability in culture. Adopting an unbiased approach we screened polymer microarrays and identified a polyurethane matrix which promoted hepatic endoderm viability, hepatocellular gene expression, drug inducible metabolism and function. We have identified a manufacturable sub-cellular matrix capable of supporting long-term differentiated cell function which represents a step forward in developing scalable and phenotypicaly stable hESC derived hepatocytes.</gtr:description><gtr:id>31570B81-E08A-4004-9D45-71BFE62DCE73</gtr:id><gtr:impact>We have employed ActivinA and Wnt3a signalling to produce efficient levels of hepatocyte like cells (approximately 90%) which display hepatic function, including: ureagenesis, gluconeogenesis, albumin secretion and CYP1A2 activity from hESCs and iPSCs (Hay etal.,2008 ; Sullivan etal.,2010). Although hepatic endoderm (HE) generated from hESCs and iPSCs is a genotypically diverse, cheap and stable source of &amp;quot;hepatocytes&amp;quot;, HE routine application is limited due to phenotypic instability in culture. Adopting an unbiased approach we screened polymer microarrays and identified a polyurethane matrix which promoted hepatic endoderm viability, hepatocellular gene expression, drug inducible metabolism and function. We have identified a manufacturable sub-cellular matrix capable of supporting long-term differentiated cell function which represents a step forward in developing scalable and phenotypicaly stable hESC derived hepatocytes.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>iPSC &amp; HuESC derived hepatocytes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A34E769-2D4C-48FE-B19A-62052E9C34F6"><gtr:id>9A34E769-2D4C-48FE-B19A-62052E9C34F6</gtr:id><gtr:title>Regression of Liver Fibrosis.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c43f9538db5bdad65f025ba2fd94131b"><gtr:id>c43f9538db5bdad65f025ba2fd94131b</gtr:id><gtr:otherNames>Campana L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F4E9C1C-4ED3-462D-9782-7094EA59A91D"><gtr:id>1F4E9C1C-4ED3-462D-9782-7094EA59A91D</gtr:id><gtr:title>Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f37697b0f9be7a9abefc1217f1cecb1"><gtr:id>6f37697b0f9be7a9abefc1217f1cecb1</gtr:id><gtr:otherNames>Schrader J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CEB3A5BC-2567-41C4-A87D-CD10E3F5EDA8"><gtr:id>CEB3A5BC-2567-41C4-A87D-CD10E3F5EDA8</gtr:id><gtr:title>Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88DC4BF6-E5AB-4018-BECC-FAEE654EE3FE"><gtr:id>88DC4BF6-E5AB-4018-BECC-FAEE654EE3FE</gtr:id><gtr:title>p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/345238daf01c4bb5b5c19682306e87d3"><gtr:id>345238daf01c4bb5b5c19682306e87d3</gtr:id><gtr:otherNames>Kendall TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F8B5178F-22CC-4E6D-96A6-2DA5A54D977F"><gtr:id>F8B5178F-22CC-4E6D-96A6-2DA5A54D977F</gtr:id><gtr:title>Persistence of functional hepatocyte-like cells in immune-compromised mice.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f4906575ba949da2a306922a01222fe"><gtr:id>3f4906575ba949da2a306922a01222fe</gtr:id><gtr:otherNames>Payne CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAB366C4-616B-4380-BBB8-225C0FF89B37"><gtr:id>EAB366C4-616B-4380-BBB8-225C0FF89B37</gtr:id><gtr:title>Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d3c4db5444be357dea85492f795ee6a"><gtr:id>3d3c4db5444be357dea85492f795ee6a</gtr:id><gtr:otherNames>Pellicoro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DD9DFA5-6770-4F47-B12C-08792549C813"><gtr:id>8DD9DFA5-6770-4F47-B12C-08792549C813</gtr:id><gtr:title>Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cada07c08b2731874084f9b42e566470"><gtr:id>cada07c08b2731874084f9b42e566470</gtr:id><gtr:otherNames>Boulter L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E5601FFE-67B8-447C-BE97-4F11002D8A8C"><gtr:id>E5601FFE-67B8-447C-BE97-4F11002D8A8C</gtr:id><gtr:title>Hepatic changes in the failing Fontan circulation.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c864654f49adb286212da8ddbd46d80f"><gtr:id>c864654f49adb286212da8ddbd46d80f</gtr:id><gtr:otherNames>Kiesewetter CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1874CA1D-54B7-4478-8243-71F91097A273"><gtr:id>1874CA1D-54B7-4478-8243-71F91097A273</gtr:id><gtr:title>A &amp;quot;good death&amp;quot; with irreversible liver disease: Talking with patients and families about deteriorating health and dying</gtr:title><gtr:parentPublicationTitle>Clinical Liver Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3dd4d959ced6dd4fe02702d9679cdfd0"><gtr:id>3dd4d959ced6dd4fe02702d9679cdfd0</gtr:id><gtr:otherNames>Boyd K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4ADCBC2B-871D-4DF1-B22F-009FBABD613F"><gtr:id>4ADCBC2B-871D-4DF1-B22F-009FBABD613F</gtr:id><gtr:title>The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f697eb62825489ef5f105c80cef5128"><gtr:id>7f697eb62825489ef5f105c80cef5128</gtr:id><gtr:otherNames>Conti JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3E55B66-4E66-4A09-833D-345474BC3603"><gtr:id>D3E55B66-4E66-4A09-833D-345474BC3603</gtr:id><gtr:title>Standing down the guard: stellate cells leave quietly.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e684d532be211c96de7034164e903f15"><gtr:id>e684d532be211c96de7034164e903f15</gtr:id><gtr:otherNames>Henderson NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61D6ECBF-4FB8-4E2A-B333-9AABF553F36A"><gtr:id>61D6ECBF-4FB8-4E2A-B333-9AABF553F36A</gtr:id><gtr:title>Liver fibrosis: a bidirectional model of fibrogenesis and resolution.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40861A85-4B89-4828-81DD-919136760B62"><gtr:id>40861A85-4B89-4828-81DD-919136760B62</gtr:id><gtr:title>Generation of functional human hepatic endoderm from human induced pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0aa9fc0d5829ea2fc6649714a4512605"><gtr:id>0aa9fc0d5829ea2fc6649714a4512605</gtr:id><gtr:otherNames>Sullivan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD160CB7-A1FE-40A7-A45B-7534B3B3133D"><gtr:id>DD160CB7-A1FE-40A7-A45B-7534B3B3133D</gtr:id><gtr:title>Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ada737d9218e84fe6bff5d61e0264ec"><gtr:id>1ada737d9218e84fe6bff5d61e0264ec</gtr:id><gtr:otherNames>Fallowfield JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3887AA4-52C9-46CF-9718-81291CECA135"><gtr:id>D3887AA4-52C9-46CF-9718-81291CECA135</gtr:id><gtr:title>Polymer Supported Directed Differentiation Reveals a Unique Gene Signature Predicting Stable Hepatocyte Performance.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88faafb158d268b797c8d4d26509a188"><gtr:id>88faafb158d268b797c8d4d26509a188</gtr:id><gtr:otherNames>Villarin BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15F9F680-BDE0-46AB-833B-0EE1F65663D5"><gtr:id>15F9F680-BDE0-46AB-833B-0EE1F65663D5</gtr:id><gtr:title>Alcohol and global health: focus on acute pancreatitis needed.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e39af20db622417a90e55db58ade5112"><gtr:id>e39af20db622417a90e55db58ade5112</gtr:id><gtr:otherNames>Mole D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96C6CF49-6980-48D9-84D6-94F9C0F45DBE"><gtr:id>96C6CF49-6980-48D9-84D6-94F9C0F45DBE</gtr:id><gtr:title>Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e684d532be211c96de7034164e903f15"><gtr:id>e684d532be211c96de7034164e903f15</gtr:id><gtr:otherNames>Henderson NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8F57EE9-133C-4B47-95C0-76F87115EAE7"><gtr:id>D8F57EE9-133C-4B47-95C0-76F87115EAE7</gtr:id><gtr:title>Galectin-3 regulates hepatic progenitor cell expansion during liver injury.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63a9607108301cf15df359f7af63a7c0"><gtr:id>63a9607108301cf15df359f7af63a7c0</gtr:id><gtr:otherNames>Hsieh WC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D847A65A-FF16-4EDF-8023-E8EF2D1C6D80"><gtr:id>D847A65A-FF16-4EDF-8023-E8EF2D1C6D80</gtr:id><gtr:title>Unexpectedly high incidence of indigenous acute hepatitis E within South Hampshire: time for routine testing?</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c00edf3ec7a44fbd420cd0ecf1dd8667"><gtr:id>c00edf3ec7a44fbd420cd0ecf1dd8667</gtr:id><gtr:otherNames>De Silva AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D19DE629-E133-43B6-8BCC-5F9430A0D833"><gtr:id>D19DE629-E133-43B6-8BCC-5F9430A0D833</gtr:id><gtr:title>Maternal Smoking Dysregulates Protein Expression in Second Trimester Human Fetal Livers in a Sex-Specific Manner.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1069c5c4fc1b4d2f049a55c3dd4c080e"><gtr:id>1069c5c4fc1b4d2f049a55c3dd4c080e</gtr:id><gtr:otherNames>Filis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F362CE1-D97C-4B7E-93E8-1BC48D62EF03"><gtr:id>9F362CE1-D97C-4B7E-93E8-1BC48D62EF03</gtr:id><gtr:title>Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/482af3eb67f4ca194e8027d61bd41d29"><gtr:id>482af3eb67f4ca194e8027d61bd41d29</gtr:id><gtr:otherNames>Gibbons MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B5487A3-00A8-4DC9-BEE4-ADF872E0733D"><gtr:id>1B5487A3-00A8-4DC9-BEE4-ADF872E0733D</gtr:id><gtr:title>Galectin-3 regulates myofibroblast activation and hepatic fibrosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e684d532be211c96de7034164e903f15"><gtr:id>e684d532be211c96de7034164e903f15</gtr:id><gtr:otherNames>Henderson NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B70D2E95-6DEB-4A66-936A-E78623ACEAA3"><gtr:id>B70D2E95-6DEB-4A66-936A-E78623ACEAA3</gtr:id><gtr:title>Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6EF56212-B496-4495-AD3E-8DCF36588C6D"><gtr:id>6EF56212-B496-4495-AD3E-8DCF36588C6D</gtr:id><gtr:title>Resolution of liver fibrosis: basic mechanisms and clinical relevance.</gtr:title><gtr:parentPublicationTitle>Seminars in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0272-8087</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F9413FE-8DC1-48C3-8ABE-7441F35CAE08"><gtr:id>0F9413FE-8DC1-48C3-8ABE-7441F35CAE08</gtr:id><gtr:title>Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE61097D-65F3-4B46-8D94-4882096F0E7D"><gtr:id>BE61097D-65F3-4B46-8D94-4882096F0E7D</gtr:id><gtr:title>Origins of fibrosis: pericytes take centre stage.</gtr:title><gtr:parentPublicationTitle>F1000prime reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3a3cd6ecba1b091648e53a98f6d06be"><gtr:id>c3a3cd6ecba1b091648e53a98f6d06be</gtr:id><gtr:otherNames>Greenhalgh SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2051-7599</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8CEEB61-D58A-45E3-9B83-5A707B58159F"><gtr:id>D8CEEB61-D58A-45E3-9B83-5A707B58159F</gtr:id><gtr:title>Liver fibrosis: Therapeutic armory 40 years on</gtr:title><gtr:parentPublicationTitle>Clinical Liver Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2dd5f863a232bfdbc85129a01e8dc8c2"><gtr:id>2dd5f863a232bfdbc85129a01e8dc8c2</gtr:id><gtr:otherNames>Iredale J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0601AD34-4D92-437C-8EF9-B8377DC7217C"><gtr:id>0601AD34-4D92-437C-8EF9-B8377DC7217C</gtr:id><gtr:title>Metabolic pathways promoting intrahepatic fatty acid accumulation in methionine and choline deficiency: implications for the pathogenesis of steatohepatitis.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/755bdde6415bf0bc5b52b495bf44f964"><gtr:id>755bdde6415bf0bc5b52b495bf44f964</gtr:id><gtr:otherNames>Macfarlane DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0193-1849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CD2BF50-7428-4843-A332-4AF54BAA4743"><gtr:id>4CD2BF50-7428-4843-A332-4AF54BAA4743</gtr:id><gtr:title>Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a836613a298ad0d98ea43821e75d23a4"><gtr:id>a836613a298ad0d98ea43821e75d23a4</gtr:id><gtr:otherNames>Ramachandran P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65070EB1-4B51-4787-8394-F74DB4D471DD"><gtr:id>65070EB1-4B51-4787-8394-F74DB4D471DD</gtr:id><gtr:title>Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e34b56bab81ef0a4e575d2ff9164e434"><gtr:id>e34b56bab81ef0a4e575d2ff9164e434</gtr:id><gtr:otherNames>Hay DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91D44FC5-E899-44B4-B630-CD7280571DA3"><gtr:id>91D44FC5-E899-44B4-B630-CD7280571DA3</gtr:id><gtr:title>Twelve tips for teachers to encourage student engagement in academic medicine.</gtr:title><gtr:parentPublicationTitle>Medical teacher</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f0b37b7192d0d74681f8917b52e3765"><gtr:id>5f0b37b7192d0d74681f8917b52e3765</gtr:id><gtr:otherNames>Lawson McLean A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-159X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96C48563-C13B-4B53-8958-63D2E02B287B"><gtr:id>96C48563-C13B-4B53-8958-63D2E02B287B</gtr:id><gtr:title>Stellate Cells in Health and Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c43f9538db5bdad65f025ba2fd94131b"><gtr:id>c43f9538db5bdad65f025ba2fd94131b</gtr:id><gtr:otherNames>Campana L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780128001349</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A58A0B6E-A86D-4712-A25A-B0D1A7AAED14"><gtr:id>A58A0B6E-A86D-4712-A25A-B0D1A7AAED14</gtr:id><gtr:title>Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB8A2B7E-0B90-4F2E-9292-590D5437A71A"><gtr:id>DB8A2B7E-0B90-4F2E-9292-590D5437A71A</gtr:id><gtr:title>Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e34b56bab81ef0a4e575d2ff9164e434"><gtr:id>e34b56bab81ef0a4e575d2ff9164e434</gtr:id><gtr:otherNames>Hay DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CF1B038-F5D6-43AA-8098-B1D5C9BCD9A0"><gtr:id>3CF1B038-F5D6-43AA-8098-B1D5C9BCD9A0</gtr:id><gtr:title>Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/345238daf01c4bb5b5c19682306e87d3"><gtr:id>345238daf01c4bb5b5c19682306e87d3</gtr:id><gtr:otherNames>Kendall TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51383548-249B-428F-9C54-0BBCB8537F75"><gtr:id>51383548-249B-428F-9C54-0BBCB8537F75</gtr:id><gtr:title>Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5560243215006bfb22466aeb12c49fd4"><gtr:id>5560243215006bfb22466aeb12c49fd4</gtr:id><gtr:otherNames>Bird TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB7B1D72-9D20-4D06-948E-B97B571037D2"><gtr:id>FB7B1D72-9D20-4D06-948E-B97B571037D2</gtr:id><gtr:title>Reversibility of liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Fibrogenesis &amp; tissue repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d3c4db5444be357dea85492f795ee6a"><gtr:id>3d3c4db5444be357dea85492f795ee6a</gtr:id><gtr:otherNames>Pellicoro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1755-1536</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB61AF75-582D-43BA-9C90-4B7CC4C56A20"><gtr:id>FB61AF75-582D-43BA-9C90-4B7CC4C56A20</gtr:id><gtr:title>The bone marrow functionally contributes to liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e856f187c428b37710fb66859cf2d23"><gtr:id>1e856f187c428b37710fb66859cf2d23</gtr:id><gtr:otherNames>Russo FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/351F0000-241D-417A-BD63-78B17A52CF23"><gtr:id>351F0000-241D-417A-BD63-78B17A52CF23</gtr:id><gtr:title>Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76f42213696de46d16431f7316cb7d40"><gtr:id>76f42213696de46d16431f7316cb7d40</gtr:id><gtr:otherNames>Lorenzini S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5437D6F5-18D0-4683-8698-1F5513EF6E44"><gtr:id>5437D6F5-18D0-4683-8698-1F5513EF6E44</gtr:id><gtr:title>The inhibitory role of stromal cell mesenchyme on human embryonic stem cell hepatocyte differentiation is overcome by Wnt3a treatment.</gtr:title><gtr:parentPublicationTitle>Cloning and stem cells</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6bd387f55c76db9e99830d4f5107988c"><gtr:id>6bd387f55c76db9e99830d4f5107988c</gtr:id><gtr:otherNames>Fletcher J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1536-2302</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52DD17C0-F118-4F22-B483-51460345E4D9"><gtr:id>52DD17C0-F118-4F22-B483-51460345E4D9</gtr:id><gtr:title>Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bbb6c2dbdbbbb0453b95e990fc58eae7"><gtr:id>bbb6c2dbdbbbb0453b95e990fc58eae7</gtr:id><gtr:otherNames>Thomas JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CFB7FE5-5E7F-4699-AB75-1B89C2547E59"><gtr:id>8CFB7FE5-5E7F-4699-AB75-1B89C2547E59</gtr:id><gtr:title>Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/363F95EA-89C7-4503-82E5-B461F467F261"><gtr:id>363F95EA-89C7-4503-82E5-B461F467F261</gtr:id><gtr:title>The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation.</gtr:title><gtr:parentPublicationTitle>Cellular reprogramming</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f007ef8009298a5f0c1325be38f9aee"><gtr:id>2f007ef8009298a5f0c1325be38f9aee</gtr:id><gtr:otherNames>Hannoun Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2152-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A1B3036-7321-4576-BAD8-4CA5F6719F0C"><gtr:id>3A1B3036-7321-4576-BAD8-4CA5F6719F0C</gtr:id><gtr:title>ECAT-V: where clinical and research training meet.</gtr:title><gtr:parentPublicationTitle>The Veterinary record</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21e2accb427911e44809aabeb726e938"><gtr:id>21e2accb427911e44809aabeb726e938</gtr:id><gtr:otherNames>Argyle DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-4900</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D37C864-BFE0-48CE-A571-69D377757BF9"><gtr:id>6D37C864-BFE0-48CE-A571-69D377757BF9</gtr:id><gtr:title>Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: protocol for response-adaptive randomised placebo-controlled dose-finding parallel group trial (DexFEM).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/859c4b8d34c4be4f54418d2cb29c89ce"><gtr:id>859c4b8d34c4be4f54418d2cb29c89ce</gtr:id><gtr:otherNames>Warner P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15FEB7D1-55B3-4FEC-9DB0-DE2F6D07CB4A"><gtr:id>15FEB7D1-55B3-4FEC-9DB0-DE2F6D07CB4A</gtr:id><gtr:title>Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2eb9408bb07fef7cbc71ade2fb67dda3"><gtr:id>2eb9408bb07fef7cbc71ade2fb67dda3</gtr:id><gtr:otherNames>Hartland SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC154BF2-B8DA-442E-958F-238A94614CF5"><gtr:id>BC154BF2-B8DA-442E-958F-238A94614CF5</gtr:id><gtr:title>Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8715cdc6e18b76ebe70866e3231e7367"><gtr:id>8715cdc6e18b76ebe70866e3231e7367</gtr:id><gtr:otherNames>Mole DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03175115-516E-487D-AA8B-87488A53B6E2"><gtr:id>03175115-516E-487D-AA8B-87488A53B6E2</gtr:id><gtr:title>Identifying molecular factors that contribute to resolution of liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f59ad39a086828f0c6172b2bb84d8eeb"><gtr:id>f59ad39a086828f0c6172b2bb84d8eeb</gtr:id><gtr:otherNames>Iredale JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98007067-B8C6-40AD-9EE1-05191C623508"><gtr:id>98007067-B8C6-40AD-9EE1-05191C623508</gtr:id><gtr:title>Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2161a7b82e55ae2cc0a43abe8c874d5d"><gtr:id>2161a7b82e55ae2cc0a43abe8c874d5d</gtr:id><gtr:otherNames>Zhou X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600033</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>